# Why BPC-157 Isn't FDA Approved Yet URL: https://moleculenotes.com/regulatory-and-approval-status/why-is-bpc-157-not-approved-by-fda Published: 2026-07-24 Updated: 2026-07-24 Author: Admin Category: Regulatory & Approval Status Reading time: 10 min > Why is BPC-157 not approved by FDA despite 150 studies. Discover regulatory, funding, and trial barriers that have stalled this compound for decades. --- Sometime in the early 1990s, at the University of Zagreb School of Medicine, a pharmacology group led by Professor Dijalma Sikiric began extracting partial sequences from human gastric juice protein. The hypothesis was precise: endogenous gastric proteins might encode peptide sequences with intrinsic tissue-protective activity. One 15-amino-acid fragment, eventually designated BPC-157, would go on to accumulate roughly 150 peer-reviewed publications over three decades. It has never been approved for human use anywhere on earth. That gap, between a substantial preclinical record and zero approved clinical applications, is the central puzzle. The answer is not a simple one. It involves [intellectual property law](https://www.wipo.int/patents/en/), the economics of drug development, the structural limitations of a single academic program, and the long, expensive distance between a rat model and a Phase III trial. The word "conspiracy" does not enter the picture. The word "structure" does, repeatedly. ## What BPC-157 Actually Is BPC-157 is a synthetic pentadecapeptide, meaning a chain of exactly 15 amino acids. Its sequence, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, was derived from a partial sequence of human gastric juice protein BPC. That sequence does not occur in isolation in nature. Sikiric's group designed and stabilized it for experimental purposes, which distinguishes it from endogenous peptides that arise naturally within the body. One pharmacological feature drew early attention from gastroenterology researchers. BPC-157 is stable in human gastric juice and resists enzymatic degradation without requiring PEGylation or cyclization, the chemical modifications that most therapeutic peptides need to survive the gastrointestinal environment. That oral stability profile was unusual and scientifically interesting. The Zagreb group applied the compound across an exceptionally broad range of animal model conditions: gastric and duodenal ulcers, inflammatory bowel disease models, tendon-to-bone healing, ligament repair, peripheral nerve regeneration, corneal injury, and skin wound healing. The breadth of application across tissue types is precisely what makes the clinical translation gap striking. The proposed mechanism is characterized as pleiotropic. According to published Zagreb research, BPC-157 modulates the nitric oxide system, upregulates growth factor expression through VEGF and EGF receptor pathways, and interacts with the FAK-paxillin signaling axis involved in cell migration and angiogenesis. It is not a single-receptor agonist with defined binding affinity. That distinction matters considerably when a compound eventually faces regulatory review. ## 150 Papers, One Laboratory: The Zagreb Research Record Roughly 150 peer-reviewed publications have accumulated around BPC-157 since 1991. The overwhelming majority originate from, or cite directly, the University of Zagreb group under Sikiric. That concentration is not a minor methodological footnote. Peer commentators assessing the evidence base have identified it as a recognized limitation. Publication volume grew steadily from the mid-1990s through the 2010s, with the Zagreb laboratory accounting for the dominant share across every period. Independent confirmatory studies from outside Zagreb have appeared, particularly on tendon healing and neuroprotection, lending partial external validation. But independent papers remain a modest fraction of the total count, and no external group has run a full dose-response replication study in parallel with the original Zagreb protocols. The funding structure explains much of the concentration. The program has operated on Croatian Ministry of Science grants and University of Zagreb institutional support. That resource base is constrained relative to pharmaceutical industry-backed programs or NIH-funded multicenter consortia. Publication volume accumulated because the Zagreb group was productive and consistent. Multicenter replication did not accumulate because no equivalent institutional infrastructure existed to fund it. These numbers highlight a pattern worth examining directly. A publication record of 150 papers is substantial. A publication record where one institution accounts for the dominant share, with limited independent replication of key dose-response findings, is a different kind of scientific standing than 150 papers distributed across 40 research groups in 15 countries. ### Why is BPC-157 not approved by FDA when animal models have not translated to human trials Animal models establish proof-of-concept. They are the necessary first stage of drug development, not the final one. Before regulatory agencies in any jurisdiction will approve a compound for human use, they require a sequence of [human trial data](https://www.fda.gov/patients/drug-development-process): Phase I trials establishing safety in a small cohort, Phase II trials identifying an efficacy signal in a target population, and Phase III trials confirming controlled efficacy at scale. The BPC-157 clinical trial record contains one entry of note. A Phase II trial for inflammatory bowel disease was initiated. As of available public records, results from that trial have not appeared in any peer-reviewed journal. The entire published evidence base therefore remains at the animal-model level. One specific feature of the preclinical data draws both interest and scrutiny. The Zagreb group's rodent studies consistently demonstrate dose-dependent activity at nanogram-to-microgram per kilogram ranges. Most approved peptide drugs require milligram-per-kilogram dosing. That potency claim is scientifically notable, but it also raises unresolved questions about dose extrapolation to human pharmacokinetics. No published human pharmacokinetic data exist for BPC-157. The scientific community has no confirmed bioavailability figure, no established half-life, and no characterized metabolite profile in humans. Preclinical potency, however striking in rodent models, cannot substitute for that data. ## The Patent Problem and the Funding Catch-22 Pharmaceutical drug development is expensive at every stage, and prohibitively expensive at Phase III. A single Phase III trial can cost between $50 million and several hundred million dollars. Academic laboratories do not have that capital. Pharmaceutical companies do, but they typically deploy it only when patent-protected market exclusivity makes the investment economically rational. BPC-157 faces a structural problem at precisely this junction. The peptide is derived from a naturally occurring human protein sequence. Patenting naturally derived peptide sequences faces significant legal obstacles under current [intellectual property frameworks](https://www.uspto.gov/patents/) in both the United States and the European Union. Without a defensible patent position, a pharmaceutical company funding a Phase III trial would be funding the development of a compound that competitors could manufacture the day after approval. The commercial logic does not hold. The result is a funding catch-22. Academic labs lack the capital for Phase III trials. Pharmaceutical companies lack the commercial incentive to fund them. BPC-157 sits in the space between: too novel for off-patent generics pathways, too legally uncertain for industry investment. The breakdown illustrates a structural mismatch that is not unique to BPC-157 but is particularly acute here given the single-institution research base. That structural insularity compounds the problem in a second way. Multicenter collaboration, institutional partnerships, and industry licensing discussions typically require a broad network of research groups with independent stakes in the compound's development. A program concentrated in one laboratory at one university in one country generates fewer of those relationships. Grant applications, partnership negotiations, and licensing discussions all become harder to initiate from a narrower base. ## What Regulatory Approval Actually Requires The FDA's Investigational New Drug application process requires a defined preclinical data package before human trials can begin. That package must include toxicology data from multiple species, a characterized mechanism of action, a defined dose-response relationship, and manufacturing specifications sufficient to ensure consistent compound identity. BPC-157 has satisfied some of these requirements in the published preclinical literature. It has not satisfied all of them to the standard a full IND submission would demand. Pleiotropic compounds face additional regulatory difficulty. Agencies want a defined molecular target. They want a predictable dose-response curve tied to a specific biological pathway. They want a safety profile that is interpretable in mechanistic terms. BPC-157's broad-spectrum activity across multiple signaling pathways is scientifically interesting and also, from a regulatory standpoint, difficult to characterize in the narrative a submission requires. Neither the FDA nor the European Medicines Agency has received or approved a full IND or Clinical Trial Authorization application for BPC-157, based on available public records. The EMA framework is relevant given the European origin of the research, but the compound has not advanced through either agency's formal review process. The absence of regulatory approval in any jurisdiction has not prevented the compound from circulating in biohacking and bodybuilding communities, where it is sold as a research chemical. That market did not emerge from the Zagreb academic program and was not designed or endorsed by it. It exists because regulatory absence creates a vacuum, and commercial actors fill vacuums. The scientific situation, to be precise, is that no established human dosing regimen exists, no confirmed human pharmacokinetics exist, and no regulatory body has evaluated the compound for human safety. ## What Would Need to Happen for Clinical Translation The scientific and institutional steps required for BPC-157 to reach approved clinical status are identifiable, even if the likelihood of each remains uncertain. Independent multicenter replication of key animal model findings would need to be published, with full dose-response characterization conducted outside the Zagreb group's protocols. Published Phase I safety data in humans would need to exist. At least one completed Phase II trial with peer-reviewed results would need to enter the public record. None of those conditions currently obtain. Mechanism clarification would also be required before any serious Phase III submission. The pleiotropic modulator hypothesis is scientifically defensible as a working framework. It is insufficient as a regulatory submission narrative. Identifying a primary molecular target, even within a pleiotropic system, would give regulators and funders a more tractable characterization of what the compound actually does and why. Three institutional pathways could theoretically change the situation. A pharmaceutical partner willing to navigate the patent landscape and accept the IP risk could fund a clinical program. A government-funded clinical initiative, analogous to NIH-sponsored trials for unpatentable compounds, could bypass the commercial incentive problem. An academic consortium with sufficient multicenter infrastructure could generate the independent replication and human safety data that currently do not exist. Comparing BPC-157's trajectory against peptides that did achieve approval makes the gap concrete. Peptides such as oxytocin, cyclosporine, and more recently semaglutide reached Phase III and approval through combinations of clear molecular targets, patent-protected structural modifications, and substantial industry investment. BPC-157 has none of those conditions currently in place. These numbers highlight why the structural gap between preclinical promise and regulatory approval is not a matter of scientific evidence alone. Whether any of those pathways will open is a genuinely open question. Thirty years of preclinical evidence is neither confirmation of clinical futility nor a guarantee of eventual approval. Several researchers outside Zagreb have noted the compound's unusual stability and potency profile as scientifically worth pursuing. Several others have noted the replication gaps and mechanism ambiguity as reasons for caution. Both positions are supported by the available record. BPC-157 occupies an unusual position in biomedical research. Three decades of animal-model data, a coherent if incompletely characterized mechanism, and a publication record that is simultaneously substantial and structurally narrow. The absence of FDA or EMA approval reflects interlocking constraints: the patent landscape for naturally derived sequences, the funding gap between academic research and Phase III trials, the concentration of the research program in a single institution, and the absence of published human trial data. Why is BPC-157 not approved by FDA or any equivalent agency after 30 years? The answer is not one thing. It is the compound sitting at the intersection of intellectual property law, academic resource constraints, regulatory complexity, and an incomplete clinical record. Whether those constraints will eventually be overcome depends on questions that remain, as of this writing, unanswered. The story is not yet finished. It is also not yet close to its next chapter. **Stay current on peptide chemistry research.** Subscribe to the Molecule Notes newsletter for rigorous, sourced analysis of preclinical findings, regulatory developments, and the open questions shaping the field.